1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
CG Invites Co., Ltd.

CG Invites Co., Ltd.

KKRX:083790
871.00
KRW
-17.00
(-1.91%)
-167.71EPS
114.03BMarket Cap
CG Invites Co., Ltd.
KRX:083790
(Korea Stock Exchange)

Recent

price

871.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
126.13
120.06
106.11
132.62
109.98
132.17
289.8
236.02
250.64
233.78
378.9
618.29
62.46
65.91
94.42
357.86
372.05
Revenue per Share
-153.76
-298.06
-336.5
-315.41
-289.29
-104.47
-43.48
-166.24
124.67
-627.33
-123.33
-232
-345
-661
-671
-46
-41.96
Basic EPS, GAAP
-384.48
-305.86
-189.18
-194.53
-94.78
-109.98
-179.7
-178.03
-27.78
-130.58
-317.68
-322.74
-564.9
-756.18
-465.96
-331.91
-324.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.3
- -
- -
- -
32.81
- -
- -
Dividend per Share
1,573.11
887.65
637.87
938.92
1,223.19
1,473.9
1,613.92
1,764.03
3,033.47
2,394.89
3,102.04
3,072.05
2,732.32
1,898.18
1,281.21
1,367.5
1,309.34
Book Value per Share
659.79
537.2
363.43
757.44
1,107.44
1,322.23
1,477.37
1,685.94
3,011.37
2,112.65
2,935.81
2,922.09
2,609.96
1,876.23
1,167.96
1,145.39
1,086.39
Tangible Book Value per Share
27
32
35
36
41
46
50
52
55
60
80
69
69
74
77
77
77
Basic Weighted Avg Shares
3,371
3,806
3,719
4,796
4,536
6,136
14,525
12,175
13,887
14,007
30,223
42,376
4,321
4,879
7,253
27,391
28,599
Sales/Revenue/Turnover
-125.02
-257.72
-193.88
-125.92
-159.37
-65.05
-28.14
-52.66
12.65
-75.39
-33.55
-28.82
-553.94
-644.41
-530.62
-95.28
-94.49
Operating Margin (%)
413
1,299
1,657
1,402
1,362
1,318
1,698
1,220
1,259
1,846
4,916
2,995
3,480
3,199
4,250
6,608
6,580
Depreciation Expense
-4,109
-9,448
-11,794
-11,406
-11,931
-4,850
-2,179
-8,575
6,908
-37,585
-9,838
-15,901
-23,869
-48,924
-51,544
-3,521
-3,225
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
3.36
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-121.91
-248.25
-317.13
-237.82
-263.05
-79.04
-15
-70.43
49.74
-268.34
-32.55
-37.52
-552.35
-1,002.81
-710.63
-12.85
-11.28
Profit Margin (%)
15,455
18,455
-4,140
6,177
351
-523
-542
17,526
156,500
103,612
109,442
78,452
18,017
1,104
-4,134
-43,603
-47,271
Working Capital
4,146
12,008
500
32,047
13,512
9,459
1,863
7,800
31,286
12,537
14,763
24,399
20,508
29,889
42,396
1,162
865
LT Debt
42,018
30,371
22,374
36,164
55,028
73,639
83,265
91,587
184,467
225,217
220,415
214,626
193,423
145,293
120,799
118,675
112,842
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
1.02
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
4.86
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-9.33
-26.1
-44.72
-38.97
-26.17
-7.64
-2.81
-9.85
5.03
-22.61
-5.41
-7.53
-12.05
-29.33
-42.28
-3.46
-3.32
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
44,392
45,299
45,032
LT Borrowings
- -
- -
- -
LT Finance Leases
339
1,162
865
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
77
77
77
Market Capitalization
126,106
114,342
114,034

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
48,239
45,865
40,927
Cash, Cash Equivalents & STI
20,289
19,599
17,424
Accounts Receivable, Net
5,246
7,948
4,370
Inventories
11,835
6,418
7,835
Total Current Liabilities
107,850
89,467
88,198
Payables & Accruals
- -
- -
- -
ST Debt
44,392
45,299
45,032
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.84%
-11.2%
-1.76%
Free Cash Flow
66.94%
8.42%
-29.02%
Net Income, GAAP
-53.12%
25.78%
-93.17%
Sales/Revenue/Turnover
54.09%
57.92%
277.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
709
2,180
1,629
2,735
7,253
2025
2,459
6,179
6,128
12,004
27,391
2026
4,289
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-98
-185
-96
-291.35
-671
2025
-62
-134
-158.99
309.01
-46
2026
-58.16
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
32.81
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
CG Invites Co., Ltd. (083790.KQ) engages primarily in the discovery, development, and commercialization of biopharmaceuticals using structural chemoproteiomics-based platforms in South Korea. The company develops small molecule drugs, monoclonal antibodies, and other therapies targeting cancer, inflammatory diseases, infections, diabetes, hypoxia, obesity, fibrosis, and rheumatology; key pipelines include the PD-1 inhibitor camrelizumab (Phase 3 for non-small cell lung cancer), HDAC inhibitor ivaltinostat (Phase 2 for myelodysplastic syndromes), CG-652 (Phase 1 for rheumatoid arthritis), GC-745 (Phase 1 for fibrosis), and polmacoxib/tramadol hydrochloride combination (Phase 1 for osteoarthritis), alongside approved products like COX-2 inhibitors. It operates through pharmaceutical research and development, manufacturing, and sales segments, supplemented by real estate leasing and clinical trial analysis services; the company manufactures and wholesales finished drug products, hot packs, and household items. Founded in 2000 and headquartered in Seoul (38 Magokjungang 8-ro, Gangseo-gu), it employs 83 people and lists on KOSDAQ, focusing on domestic and international markets with products approved in South Korea and China. Recent developments include a 2023 sale of a 20% stake to Invites Healthcare Group for expansion into digital genomics and personalized medicine, a 2024 stock purchase agreement with Huons as part of PanGen investments to bolster biopharma capabilities, and a strategic shift toward digital genome-based therapies like Acelex, Ivaltinostat, and Camrelizumab as of 2025.